Girentuximab

Drug Profile

Girentuximab

Alternative Names: Chimeric-monoclonal-antibody-G250; Monoclonal antibody G250; Rencarex; WX-G250

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Centocor
  • Developer Heidelberg Pharma AG
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Immunostimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Suspended Renal cancer

Most Recent Events

  • 20 Sep 2017 Girentuximab is available for licensing as of 20 Sep 2017. http://www.wilex.com
  • 25 Apr 2016 Girentuximab is available for licensing as of 25Apr 2016. http://www.wilex.com
  • 08 Nov 2013 Girentuximab is available for licensing as of 08 Nov 2013. http://www.wilex.de
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top